<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="127870">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT02060175</url>
  </required_header>
  <id_info>
    <org_study_id>1-2013-0076</org_study_id>
    <nct_id>NCT02060175</nct_id>
  </id_info>
  <brief_title>Comparison of the 3-month Strut Coverage After Coronary Stenting by Optical Coherence Tomography; Cilotax and DESyne</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>Yonsei University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Yonsei University</source>
  <oversight_info>
    <authority>Korea: Institutional Review Board</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      We will compare the stent coverage at 3 months by optical coherence tomography (OCT) between
      the Cilotax and DESyne drug-eluting stents (DES). The extent of the strut uncoverage has not
      been evaluated yet for both the Cilotax and DESyne and we first sought to decide the
      reference intervals using 40 samples (total 44 patients for each group considering 10%
      drop-out rate) as the pilot study.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date>February 2014</start_date>
  <completion_date type="Anticipated">February 2016</completion_date>
  <primary_completion_date type="Anticipated">February 2016</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Stent coverage</measure>
    <time_frame>up to 3 months after stent implantation</time_frame>
    <safety_issue>No</safety_issue>
    <description>The percentage of stent uncoverage measured by OCT</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">44</enrollment>
  <condition>Patients in the Treatment of Subjects With All-comer Who Are to Undergo PCI</condition>
  <arm_group>
    <arm_group_label>1  CILOTAX arm</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Cilotax drug-eluting stents implantation</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2  DESyne arm</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>DESyne drug-eluting stents implantation</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Cilotax drug-eluting stents implantation</intervention_name>
    <arm_group_label>1  CILOTAX arm</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>DESyne drug-eluting stents implantation</intervention_name>
    <arm_group_label>2  DESyne arm</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients â‰¥ 20 years old

          -  Patients in the treatment of subjects with all-comer who are to undergo PCI

        Exclusion Criteria:

          -  Pregnant women or women with potential childbearing

          -  Life expectancy &lt; 1 year
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Hong Myeong-Ki, MD, PhD</last_name>
    <phone>082)-02)-2228-8460</phone>
    <email>mkhong61@yuhs.ac</email>
  </overall_contact>
  <location>
    <facility>
      <name>Division of Cardiology, Yonsei Cardiovascular Hospital, Yonsei University College of Medicine</name>
      <address>
        <city>Seoul</city>
        <zip>120-752</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Myeong-Ki Hong, MD, PhD</last_name>
      <phone>082)-02)-2228-8460</phone>
      <email>mkhong61@yuhs.ac</email>
    </contact>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>February 2014</verification_date>
  <lastchanged_date>February 9, 2014</lastchanged_date>
  <firstreceived_date>February 7, 2014</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Optical coherence tomography, Drug-eluting stent, Strut coverage</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
